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Abstract 
Past viewpoints on Trichomonas vaginalis infection have characterized the associated clinical disease as a 
“nuisance” condition, with affected demographics largely being older African American females residing in urban 
centers. The advent of commercial molecular assays specific for T. vaginalishas offered a new outlook 
on trichomoniasis. Within high-prevalence sexually transmitted infection populations, parasite distribution is not 
localized to specific population centers, and T. vaginalis prevalence is elevated among both younger and older 
age groups. Adaptation of these molecular assays can additionally facilitate male screening and subsequent 
epidemiologic characterization. These findings, combined with associations between T. vaginalis infection 
and human immunodeficiency virus (HIV) acquisition/transmission and persistent human 
papillomavirus infection, support consideration of the expansion of T. vaginalis screening efforts in the realms of 
clinical practice and public health. 
Introduction 
The French microscopist, clinician, and researcher A. F. Donné discovered the protozoan T. 
vaginalis 180 years ago. Trichomoniasis, the clinical entity ascribed to the pathogen, has become the 
most prevalent non-viral sexually transmitted infection (STI) in the United States (Fig. 1). A surveillance 
study conducted by the U.S. Centers for Disease Control and Prevention (CDC) in 2008 estimated 
trichomoniasis prevalence in this country at 4 million cases, with approximately 1 million new cases 
of T. vaginalis infection being diagnosed annually.1 As will be posited and further described throughout 
this review, several factors impact the true characterization of trichomoniasis. As an introductory 
example, T. vaginalis prevalence rates are rather disparate on a worldwide basis. In contrast to reports 
of >20% prevalence in some U.S., African, and indigenous Australian population centers,2,3,4,5 a number 
of European, Asian-Pacific, and non-indigenous Australian studies have documented rates lower than 
5%.6,7,8,9,10 
 
 
Figure 1. Estimated prevalence of STI in the United States 
(adapted from reference 75 with permission of the publisher). 
The advent of molecular-based laboratory detection of T. vaginalis has broadened our knowledge of 
trichomoniasis, allowing new perspectives on disease epidemiology and opportunities for prevention. 
In addition, advancements related to diagnostic algorithms have garnered much attention in the 
clinical research setting. A PubMed primary literature search (U.S. National Library of Medicine and the 
National Institutes of Health) conducted in February 2016 using the search parameter “Trichomonas 
vaginalis” filtered by the possibility of “antigen,” “molecular testing,” “nucleic acid hybridization,” 
“PCR,” “nucleic acid amplification testing,” “LAMP” (loop-mediated isothermal amplification), or 
“transcription-mediated amplification” selected 629 primary citations from the years 1964 to 2016, 
with over 25% published since the beginning of 2012. This brief commentary, with focus largely on 
literature published within the past 3 years, discusses updates on T. vaginalisepidemiology 
and laboratory testing. 
Epidemiology 
Females 
Trichomoniasis can be characterized by a diffuse, malodorous, yellow-green vaginal discharge with 
vulvar irritation.11 While pruritis and dysuria may be present, a majority of T. vaginalis infections are 
actually thought to be asymptomatic. This has long been a source of consternation for clinicians and 
researchers in the context of proper laboratory diagnostic strategies and clinical management. Data 
published nearly 25 years ago stated that approximately one-third of patients with asymptomatic T. 
vaginalis infection become symptomatic within 6 months,12 perhaps necessitating additional 
encounters with health care. Mathematic modeling suggests that the average duration of T. 
vaginalis infection in women approaches 3 to 5 years.13 
 
Such data imply indolent T. vaginalis infection in a significant percentage of women, yet the organism 
has been associated with pregnancy complications, including preterm delivery, low-birth-
weight delivery, and delivery of offspring later diagnosed with intellectual disability or attention deficit-
hyperactivity disorder.reviewed in reference 14 From a retrospective audit of 108,346 Medicaid recipients [15] 
it was concluded that females diagnosed with trichomoniasis within the first 7 months of pregnancy 
were more likely to deliver at ≤33 weeks of gestation (hazard ratio, 1.22 [95% confidence interval, 1.02 
to 1.46]), while those diagnosed within the first 8 months of pregnancy were more likely to deliver late 
pre-term (33 to 36 weeks; hazard ratio, 1.59 [95% confidence interval, 1.18 to 2.14]). In single-site 
studies of South African and U.S. females,reviewed in reference 14 T. vaginalis associations with pelvic 
inflammatory disease in HIV-positive patients, acute endometritis, and tubal infertility have been 
reported. 
 
T. vaginalis has also achieved a status of importance in the public health community. The natural 
course of human papillomavirus (HPV) infection is largely self-limiting, with 60 to 80% of infections 
becoming undetectable in 8 to 10 months.16 Prolonged or persistent HPV infections, particularly those 
involving high-risk HPV genotypes, contribute to ultimate development of cervical neoplasia. From an 
adolescent cohort, Shew et al.16 demonstrated that median time to clearance of primary HPV infection 
was 172 days in patients without concomitant T. vaginalis infection. The median value increased to 436 
days in patients with concurrent T. vaginalis infection. Donders et al.8 performed multiplex T. 
vaginalis/HPV real-time PCR on 63,251 liquid-based cytology collections from Belgian women. In 
patients with detectable high-risk HPV DNA, the likelihood of having concomitant cytology findings of 
atypical squamous cells of uncertain significance or greater (ASC-US+) was higher when T. vaginalis was 
present than when T. vaginalis was absent (odds ratio, 1.98 [95% confidence interval, 1.04 to 3.50]; P = 
0.049). Moreover, 17.8% of patients with detectable T. vaginalis DNA had cytology findings of ASC-US+, 
while only 8.7% of T. vaginalis-negative specimens had such findings (odds ratio, 2.3 [95% confidence 
interval, 1.6 to 3.2]; P < 0.0001). In an investigation of commercial sex workers in Kenya using RNA 
amplification techniques specific to both STI agents and high-risk HPV, Ting et al.17 described higher 
rates of HPV positivity in women also positive for T. vaginalis. 
 
The public health significance of T. vaginalis detection also extends to HIV. From a study of adolescents 
with behavioral risk factors for HIV infection, Mullins et al.18 reported a higher T. vaginalis incidence 
rate in females who were HIV positive (1.3/100 person months) than in those who were not (0.6/100 
person months; P = 0.002). Several studies have characterized a role for T. vaginalis in HIV acquisition 
by females. One prospective study of 4,948 sexually active African females19 reported that T. vaginalis-
infected women were more likely to test positive for HIV at a subsequent health care encounter 
(adjusted hazard ratio, 2.05 [95% confidence interval, 1.05 to 4.02]). Hughes et al.20 prospectively 
studied 3,297 African HIV-serodiscordant couples and found that T. vaginalis infection of the female 
partner was an independent risk factor for increased probability of HIV acquisition per coital act (odds 
ratio, 2.57 [95% confidence interval 1.42 to 4.65]). 
 
In similar fashion, studies have elucidated a role for T. vaginalis in HIV transmission. Co-incubation of T. 
vaginalis with acutely infected peripheral blood mononuclear cells in vitro has been shown to increase 
the HIV replication rate.21 A Louisiana cohort with documented infection by both HIV and T. 
vaginalis were prospectively observed following a course of metronidazole therapy.22 Successful anti-
trichomonad therapy (determined by T. vaginalis culture) decreased the likelihood of HIV shedding at 3 
months post-therapy compared to baseline shedding (relative risk, 0.34 [95% confidence interval, 0.12 
to 0.92]). This finding was not duplicated in HIV-positive women without antecedent T. 
vaginalis infection. Mathematical modeling of an HIV-infected population in North Carolina (with a 
presumed 22% T. vaginalis prevalence) predicted the occurrence of 0.076 HIV transmission events per 
100 HIV-positive females who test positive for T. vaginalis.23 This datum contrasts with the rate of 
0.062 HIV transmission events in HIV-positive women who are T. vaginalis negative. In the former 
scenario, 23% of HIV transmission events were attributable to T. vaginalisinfection. 
 
Compared to commonly assessed STI agents, such as Chlamydia trachomatis and Neisseria 
gonorrhoeae, the prevalence of T. vaginalis among older females is especially significant. Napierala et 
al.24 summarized clinical laboratory testing of a subacute care population within a high-prevalence STI 
community using commercially available molecular assays for C. trachomatis, N. gonorrhoeae, and T. 
vaginalis. The T. vaginalis detection rate (9.3%) within a subset of 7,277 females exceeded those of C. 
trachomatis (5.7%) and N. gonorrhoeae (1.4%; both P < 0.0002). When detection rates were delineated 
by age decade,25 the predictable finding of increased T. vaginalis detection versus C. 
trachomatis detection in patients aged 31 to 60 years was observed (Fig. 2). A T. vaginalis detection 
rate of greater than 11% was realized for females over the age of 60; however, the small subset did not 
allow statistical comparison versus C. trachomatis detection. Novel findings included elevated T. 
vaginalis detection rates in females under the age of 21 (Fig. 2) and significantly increased T. 
vaginalis detection in years 21 to 30 over that of C. trachomatis. 
 
 
Figure 2. Prevalence of Trichomonas vaginalis (solid bars), Chlamydia trachomatis(open bars), and Neisseria 
gonorrhoeae (shaded bars) among 7277 females screened by commercial transcription-mediated amplification, 
delineated by age. ‡ represents comparisons between C. trachomatis and T. vaginalis detection rates in which P 
< 0.05. 
Adapted from data published in,25 with permission from the publisher. 
Recent investigations have attempted to elucidate the T. vaginalis proclivity for older populations. 
Hearn et al.26 stratified 264 Baltimore women into age groups of 18 to 44 years and ≥45 years. The 
prevalence of T. vaginalis did not differ between the groups, yet older adults who tested positive for T. 
vaginaliswere more likely to have used marijuana (adjusted odds ratio, 3.1; P = 0.036) and 
crack cocaine (adjusted odds ratio, 3.8; P = 0.010) in the previous 6 months. In addition to general 
immunity decline during the aging process, the authors inferred a link between illicit drug use and 
increased susceptibility to infection. In vitro T. vaginalis infection models27 demonstrated suppression 
of secretory leukocyte protease inhibitor (SLPI), an agent produced by female reproductive 
tract mucosal epithelia that protects against HIV acquisition. Huppert et al.28 correlated T. vaginalis-
SLPI interaction in a clinical setting, as a >50% reduction of this marker was consistent with recurrent T. 
vaginalisinfection. The T. vaginalis-SLPI paradigm provides an additional perspective on the necessity 
for diagnosis of low-level or asymptomatic trichomoniasis. Finally, Fichorova et al.29 concluded that 
hormonal contraceptives are associated with alterations in cervical immunity that are dependent upon 
the presence of genital infections, such as trichomoniasis. In a broad sense, these immune alterations 
may increase susceptibility to HIV acquisition. The authors posit the potential impact of undiagnosed, 
asymptomatic genital tract infection on this paradigm. 
 
Past epidemiologic data, often derived from studies utilizing less sensitive diagnostic assays, have 
suggested that trichomoniasis is largely an urban disease. When considering the dataset in Fig. 2, it is 
important to note that <2% of those data were gathered from females in acute care.25 By way of STI 
phenotype calculation (defined as permutations of T. vaginalis, C. trachomatis, and N. 
gonorrhoeae detection from any health care encounter that resulted in detection of at least one STI) 
and comparison of such data25 with those from acute care30 and from a combined subacute and acute 
care cohort,31 one can ascertain parasite distribution across an entire metropolitan setting. The STI 
phenotype from subacute care demonstrated the greatest proclivity for sole detection of T. 
vaginalis (54.2% of health care encounters) (Table 1). In contrast, sole detection of T. vaginalis from 
acute care was 40.7%. Moreover, phenotypes that involved any detection of T. vaginalis were 63.5% 
and 55.8% in the subacute care and acute care populations, respectively. The above-mentioned data 
flank T. vaginalisphenotypes derived from an overall community setting.31 These separate large-scale 
data collections implicate T. vaginalis distribution as being widespread throughout a metropolitan 
setting and signal the necessity for accurate laboratory diagnostics and clinician utilization of those 
modalities. 
 
  
Table 1. High-prevalence community STI phenotypes, determined by commercial transcription-mediated 
amplification specific for Trichomonas vaginalis, Chlamydia trachomatis, and Neisseria gonorrhoeae within acute care, 
communitywide, and subacute care samplings of females positive at least one STI 
STI phenotypea Percent patient encounters by specimen source 
T. vaginalis C. trachomatis N. gonorrhoeae Acute careb Communitywidec Subacute cared 
+ − − 40.7 45.2 54.2 
+ + − 8.1 9.6 6.6 
+ − + 3.5 2.6 1.5 
+ + + 3.5 1.5 1.2 
− + − 22.2 21.0 29.1 
− + + 4.7 5.9 2.2 
− − + 17.4 14.3 4.7 
a+, positive TMA screen; −, negative TMA screen. 
bEighty-six (33.7%) encounters had at least one STI. (Data adapted from reference 30with permission of the 
publisher.) 
cTwo hundred seventy-three (35.0%) encounters had at least one STI. (Data adapted from reference 31 with 
permission of the publisher.) 
dOne thousand thirty-six (14.5%) encounters had at least one STI. (Data adapted from reference 25 with 
permission of the publisher.) 
Males 
Trichomoniasis had been largely uncharacterized in males due to a perceived lack of testing options; 
however, recent data have further elucidated clinically significant disease in males. Strockij et al.32 
studied prostatic secretions from 203 males with chronic recurrent urethroprostatitis and no 
detectable bacterial microflora. T. vaginalis was detected in 75.5% of specimens; amoeboid, spherical, 
and flagellated forms of the parasite were observed via electron microscopy. Sviben et al.33 reported 
a T. vaginalis PCR detection rate of 8.2% in 500 men with urethritis, while the rate in 200 men without 
symptoms was 2.2%. T. vaginalis can influence hypogonadism, orchitis, and male infertility.34 
 
Few data exist regarding the role of T. vaginalis in male HIV acquisition and transmission. Hobbs et al.35 
reported that the median seminal HIV RNA load in Malawi males was increased approximately 2 
log10 units in T. vaginalisurethritis. Paz-Bailey et al.36 investigated 173 HIV-positive males in South Africa 
with detectable HIV-1 RNA in genital ulcers. Those who were also infected with T. vaginalis exhibited 
increased crude viral loads over those who were not infected (mean difference, 0.62 log10 [95% 
confidence interval, 0.07 to 1.2; P = 0.027]). The role of the male sexual partner with respect to 
trichomoniasis and HIV infection should not be overlooked. Chesson et al.37 estimated that 750 
instances of new HIV infections in U.S. females were facilitated by concomitant T. vaginalis infection; 
the cost of treating T. vaginalis-attributable HIV infection is $167 million. 
 
Over the past 10 years, investigators have attempted to establish an association between 
prostate carcinoma and antecedent T. vaginalisexposure. Studies based on T. 
vaginalis seroprevalence have demonstrated modest associations with nocturia, large prostate 
volume, and benign prostatic hyperplasia/lower urinary tract symptom-related outcomes (with 
prevalence ratios ranging from 1.21 to 1.36)38 and with overall prostate cancer risk (odds ratio, 1.25).39 
Conversely, Mitteregger et al.40 detected T. vaginalis by PCR in 34% of tissue specimens with benign 
prostatic hyperplasia. Stark et al.39 described significant association between documented T. 
vaginalis infection and lethal prostate cancer (odds ratio, 6.4 [95% confidence interval, 1.5 to 27.9]) 
compared to controls with no demonstrable T. vaginalis infection. Akin to HPV triage in cervical 
carcinoma, studies may be warranted to elucidate a potential role for molecular T. vaginalis triage in 
prostate carcinoma. 
 
Within a high-prevalence STI community, 622 males were screened for C. trachomatis, N. gonorrhoeae, 
and T. vaginalis by RNA amplification;41 6.6% of the patients yielded a positive result for T. vaginalis, 
with a mean age 39.9 years (P < 0.0001 versus the mean ages for C. trachomatis and N. gonorrhoeae). 
STI agent distribution by age decade (Fig. 3) mimicked data observed in females. The authors also 
demonstrated no difference in T. vaginalis distribution within majority African American geographic 
areas of the metropolitan setting (8.9% detection rate) versus that observed in highly predominantly 
Caucasian geographic areas of the same metropolitan setting (5.0% detection rate; P = 0.15). These 
data further show the value of T. vaginalis screening with a broad demographic and geographic basis. 
 
 
Figure 3. Prevalence of Trichomonas vaginalis (solid bars), Chlamydia trachomatis(open bars), and Neisseria 
gonorrhoeae (shaded bars) among 622 males screened by commercial transcription-mediated amplification-
based methods, delineated by age. ‡ represents comparisons between T. vaginalis and C. trachomatis detection 
rates in which P < 0.05. 
Adapted from data published in [41], with permission from the publisher. 
 
Extra-urogenital detection 
Studies have characterized T. vaginalis in non-genitourinary sites. An internet-based STI surveillance 
program reported a 6.3% T. vaginalis molecular detection rate from self-collected female rectal 
swabs.42 Within a subset of these positive patients who also submitted a self-collected vaginal swab, 
100% of the vaginal swab collections were also positive for T. vaginalis (C. Gaydos, personal 
communication). Munson et al.43 reported a 2.9% T. vaginalis pharyngeal detection rate from male STI 
clinic attendees. Positive results were confirmed by a second molecular assay targeting an 
alternative T. vaginalis sequence; 85.7% of patients testing positive indicated strictly heterosexual 
preference, and 38.1% of T. vaginalis-positive pharyngeal specimens were derived from symptomatic-
patient encounters. 
Laboratory Diagnosis 
Non-molecular modalities 
The success of non-molecular means of T. vaginalis detection is largely depenent on the organism 
burden or disease prevalence. Wet-mount analysis involves collection of a vaginal swab, placement of 
the swab into physiologic saline (vaginal saline suspension), followed by microscopic observation of the 
suspension for motile flagellates using a high-power objective. This technique may have its best 
application in remote and underserved locales that may also experience financial constraints. In a 
study of Sudanese women attending a gynecologic clinic and experiencing a mean 14.4-day duration of 
symptoms, Saleh et al.3 reported 99.2% wet-mount sensitivity compared to the performance of in-
house T. vaginalis PCR. In contrast, from a London STI clinic with 9.8% T. vaginalis prevalence via a 
composite reference standard, Nathan et al. [44] reported wet-mount sensitivity of 38%. In a U.S. 
population with nearly 30% T. vaginalis prevalence, Nye et al.45 documented 54.6% wet-mount 
sensitivity compared to a composite molecular reference. Decreased sensitivity of wet mount may, in 
part, be related to the insufficient collection or missed detection of pleomorphic T. 
vaginalis developmental stages.46 
 
T. vaginalis culture is a past standard for parasite detection, with performance also predicated on the 
burden of infection or prevalence. Inoculation of vaginal saline suspensions from a population with 
approximately 85% T. vaginalis prevalence3 into Diamond's medium extrapolated to 100% analytical 
sensitivity of culture. In contrast, Nye et al.45 demonstrated 75% sensitivity of InPouch TV culture 
(BioMed Diagnostics, White City, OR) compared to a composite molecular reference. InPouch TV 
evaluation is made by direct microscopy of the culture pouch itself (without aliquoting of culture 
contents), which may facilitate testing in satellite settings. One advantage inherent to T. 
vaginalis culture is cultivation of viable organisms for nitroimidazole susceptibility testing,11 particularly 
in patients who experience treatment failure. 
 
The performance of a second non-molecular adjunct to microscopy, T. vaginalis antigen detection, is 
also dependent on geographic prevalence. In the cohort with approximately 85% T. 
vaginalis prevalence, 99.6% sensitivity of the Kalon TV latex agglutination test (Kalon Biological, Surrey, 
UK) was reported compared to PCR.3 Abu-Sarkodie et al.47 documented a kappa index of 0.93 for result 
agreement between this latex agglutination assay and InPouch TV; molecular diagnostics were not 
incorporated into the study. Jones et al.48 assessed the OSOM Trichomonas rapid test (Sekisui 
Diagnostics, San Diego, CA) using self-collected vaginal swabs from centers in South Africa and Brazil 
with T. vaginalis prevalence of 10% and 3%, respectively. Compared to a PCR reference, the OSOM 
Trichomonas rapid test demonstrated 83.3% and 68.4% sensitivity, respectively. Nathan et al.44 
documented 92% sensitivity of the OSOM Trichomonas rapid test at an STI clinic with 9.8% T. 
vaginalis prevalence. A recent investigation49 of a U.S. health care system encompassing both low- and 
high-prevalence STI locales (4.0% and 21.4% T. vaginalis detection rates, respectively) documented 
35.1% and 85.7% sensitivity of the OSOM Trichomonas rapid test in these areas, respectively. Clinician-
collected vaginal swabs submitted for antigen testing were compared to a molecular reference 
collection. In addition to the potential caveats inherent to antigen-based T. vaginalisdetection, it 
should be noted that FDA clearance has not been granted to these modalities for urine screening or for 
assessment of male specimens. 
 
Molecular modalities 
The BD Affirm VPIII Microbial Identification Test (Becton Dickinson, Sparks, MD) provides a nucleic acid 
hybridization format for detection of T. vaginalis, in addition to simultaneous assessments 
for Gardnerella vaginalis and Candida albicans. Recent studies have assessed the T. 
vaginalis component of the assay in the context of a nucleic acid amplification test (NAAT) standard. 
Within a U.S. population of females with vaginal complaints or history suggestive of STI (5% T. 
vaginalis prevalence), Andrea and Chapin50 reported 63.4% sensitivity of the BD Affirm VPIII Microbial 
Identification Test compared to a commercial NAAT. The same reference standard was employed by 
Cartwright et al.51 in evaluation of a symptomatic 320-female U.S. cohort. The BD Affirm VPIII Microbial 
Identification Test yielded 46.3% sensitivity in the population exhibiting 16.9% T. vaginalis prevalence. 
Subsequent to analytic assessments of DNA and RNA amplification efficiency, it was postulated that 
analogous differences exist between commercialized formats of these technologies.52 This concept was 
validated with an elegant set of in vitro data published by Ikeda-Dantsuji et al.53 Standardized 
quantities of C. trachomatis elementary bodies were distributed into mock clinical specimens; 
subsequent dilution series demonstrated commercial transcription-mediated amplification (TMA) 
sensitivity that was 1,000-fold greater than that of commercial PCR. This difference in sensitivity may 
also lie in the multiplicity of the target nucleic acid (in particular, rRNA targeted by commercial TMA) 
and in the removal of endogenous inhibitory agents by an oligonucleotide-based target capture 
system. 
 
Experimental differences between RNA and DNA amplification have been extrapolated to clinical 
practice. Schachter et al.54 demonstrated 44.4% sensitivity of commercial PCR for detection of N. 
gonorrhoeae from rectal specimens compared to commercial TMA. The authors reported just 60.0% 
sensitivity of commercial PCR for detection of the agent from pharyngeal swabs. Commercial TMA was 
also 12.4% and 14.8% more sensitive than strand displacement amplification (an alternative form of 
DNA amplification) in detection of N. gonorrhoeae from pharyngeal and rectal sites, respectively. Nye 
et al.45 noted a similar paradigm when assessing commercial TMA and an in-house PCR for T. vaginalis. 
Using a molecularly resolved algorithm, the sensitivities of commercial T. vaginalis TMA on 296 first-
void female urine, endocervical, and vaginal specimens were 87.5%, 89.8%, and 96.6%, respectively. 
The analogous values derived from PCR were 76.1%, 80.9%, and 83.0%. From 298 first-void male urine 
and urethral swab specimens, the sensitivity of commercial TMA ranged from 73.8% (urine) to 95.2% 
(urethral swab) when utilizing a molecularly resolved algorithm. The corresponding sensitivity data 
from PCR were 47.6% and 54.8%, respectively. The sensitivity of T. vaginalis culture from male 
specimens was 28.6%. 
 
The first FDA-cleared NAAT for T. vaginalis is the TMA-based Aptima Trichomonas vaginalis Assay 
(Hologic, San Diego, CA),55 with indications for clinician-collected vaginal swabs, endocervical swabs, 
and liquid-based cytology collections (PreservCyt solution; Cytyc Corporation, Marlborough, MA). 
Because the assay can be performed on the same collection tube as C. trachomatis/N. 
gonorrhoeae TMA, a number of laboratories have performed off-label verification of the assay on male 
first-void urine and urethral swab specimens using laboratory-defined luminescent cutoff values. 
Napierala et al.24 reported that the T. vaginalis detection rate from males did not differ significantly 
from C. trachomatis detection (P = 0.17) and was increased over N. gonorrhoeae (P = 0.006). The 
luminescent output from positive specimens did not differ significantly from the values derived from 
female testing (P ≥ 0.29). Increased clinician utilization of a laboratory-verified first-void female urine 
specimen was also noted during a 3-year testing interval.24 
 
A second FDA-cleared NAAT for T. vaginalis is the strand displacement amplification BD 
ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay (TV Qx) (BD Diagnostics, Sparks, MD). The 
indicated specimen sources include female urine, self-collected vaginal swabs, and clinician-collected 
endocervical swabs. Van Der Pol et al.56 assessed 838 self-collected vaginal swabs using TV Qx in a 
multi-center U.S. clinical trial cohort with 12.5% T. vaginalis prevalence. The kappa value between the 
TV Qx results and the data from the Aptima Trichomonas vaginalis Assay analysis of clinician-collected 
swabs from the same participants was 0.938 (P = 0.09). The sensitivity and specificity of TV Qx were 
98.3% and 99.6%, respectively. Ten specimens yielded Aptima Trichomonas vaginalis Assay-positive/TV 
Qx-negative results; the converse was true for three specimens. 
 
The AmpliVue Trichomonas Assay (Quidel, San Diego, CA) received FDA clearance in March 2015 for 
clinician-collected vaginal swabs. Following isothermal helicase-dependent amplification, T. 
vaginalis DNA is detected via lateral-flow colorimetric readout in a self-contained disposable device, 
with a turnaround time of approximately 1 hour. Unpublished data (C. Gaydos, personal 
communication) have described the performance of the AmpliVue Trichomonas Assay versus culture, 
wet mount, and the Aptima Trichomonas vaginalis Assay for 1,132 vaginal swabs. The rapid assay 
detected T. vaginalis from all specimens that were also positive by wet mount or culture analysis. 
Positive agreement with the Aptima Trichomonas vaginalis Assay data was 88.5%. 
The Xpert TV is performed on the GeneXpert system (Cepheid, Sunnyvale, CA). This DNA amplification 
assay received FDA clearance in October 2015 for female urine, self-collected vaginal swabs, and 
clinician-collected endocervical swabs. In a proof-of-concept study by Badman et al.,57 60 consecutive 
urine specimens yielding positive and negative results by an in-house T. vaginalis PCR (acquired from 
42 males and 72 females) were subjected to automated processing, cell lysis, purification, DNA 
amplification, and target detection; 97.4% overall agreement was observed, with 95% positive 
agreement. 
 
One commercialized assay for T. vaginalis molecular detection has received Conformité Européene 
marking. The AmpliSens N. gonorrhoeae/C. trachomatis/M. genitalium/T. vaginalis-Multiprime-FRT 
PCR kit (InterLabScience, Moscow, Russia) is a multiplex real-time PCR assay that requires an off-line 
DNA extraction step. Rumyantseva et al.58 investigated its performance using first-void urine from 554 
males, first-void urine from 498 females, and 209 vaginal swabs. T. vaginalis assessment was difficult 
on the basis of just one positive reference specimen in the evaluation. The assay was also limited in its 
capacity to detect Mycoplasma genitalium from both male and female specimens. 
 
Additional modalities under development include a point-of-care cartridge (Atlas Genetics, Wiltshire, 
UK) that manages DNA extraction, amplification, and detection within 30 minutes using molded 
subcircuits. The final output is an electrochemical signal obtained using differential pulse voltammetry. 
Pearce et al.59 assessed a single-analyte T. vaginalis assay with 90 self-collected vaginal swabs 
previously tested by the Aptima Trichomonas vaginalis Assay. Sensitivity and specificity indices of 
95.5% and 95.7%, respectively, were reported. The detection limit of the assay was five T. 
vaginalis organisms. As part of an investigational FilmArray nested-PCR panel for the identification of 
nine STI agents (BioFire Diagnostics, Salt Lake City, UT), Kriesel et al.60 identified T. vaginalis DNA from 
9 of 295 clinical specimens. However, not all the specimens were assessed with a predicate device. 
Finally, recent proof-of-concept studies have discussed detection of T. vaginalis by loop-mediated 
isothermal amplification61 and PCR-based microarray.62 
 
Value of T. vaginalis screening 
The CDC recommendations for T. vaginalis diagnostic testing, using highly sensitive and specific 
modalities, apply to females seeking care for vaginal discharge.11 The screening recommendations 
extend to persons receiving care in high-prevalence settings (correctional facilities and STI clinics) and 
to individuals with high-risk STI behavior (commercial sex workers, illicit drug use, and persons with 
multiple sexual partners or a history of STI). Moreover, local T. vaginalis epidemiology may influence 
screening decisions.11 
 
The scope of trichomoniasis may extend beyond these demographics, as Tomas et al.63 described 
scenarios in acute care in which STI (including T. vaginalis infection) was underdiagnosed in females in 
favor of empiric treatment for urinary tract infection. Retrospective chart reviews of 234 symptomatic 
females receiving C. trachomatis and N. gonorrhoeae screening64 revealed that only 31 were screened 
for T. vaginalis. While a laboratory diagnosis of T. vaginalis was rendered in just 1.3% (3/234) of eligible 
females, 17 patients were administered anti-trichomonad therapy (82.3% without significant 
laboratory data). Following commencement of an algorithm that automatically added T. 
vaginalis laboratory assessment to those for C. trachomatis and N. gonorrhoeae, T. vaginalis was 
detected in 18.3% (39/213) of eligible females; 95.8% of T. vaginalis laboratory diagnoses resulted in 
therapeutic regimens, while only 25% of overall anti-trichomonad regimens were administered on an 
empiric basis. Data from a high-prevalence STI community65 revealed that introduction of T. 
vaginalis TMA to the testing options resulted in a significant increase in laboratory assessments for T. 
vaginalis compared to an interval when only wet-mount testing was offered. In addition, significant 
reductions in both clinician requisition of wet-mount analysis and clinician performance of point-of-
care wet-mount microscopy was observed. Although NAAT yielded 38% more T. vaginalis detection 
than culture in one study, the prospect of universal screening may be somewhat tempered in lower-
prevalence settings.7 
 
Asymptomatic patients 
One concern about T. vaginalis molecular screening is the unnecessary laboratory diagnosis of 
asymptomatic patients,66 with a corollary being that less sensitive assays that detect higher organism 
burdens are more clinically relevant. However, Muzny et al.2 demonstrated that 58.5% of 301 females 
with wet-mount-negative/TMA-positive results reported urogenital symptoms of vaginal 
discharge, vaginal odor, and/or dysuria. This datum was similar to the 65.7% symptomatic rate of 720 
females with wet-mount-positive/TMA-positive results (adjusted odds ratio, 1.00; P = 0.98). Munson et 
al.49 reported that 56.8% of antigen assay-negative/TMA-positive patients from a low-prevalence STI 
community had symptoms of urogenital infection, while 75.0% of patients from the same setting with 
antigen assay-positive/TMA-positive results were symptomatic (P = 0.17). In addition, symptomatic 
status did not impact concordant and discordant antigen assay/TMA frequencies in a higher-
prevalence STI population (P = 0.54). These data support the hypothesis that the performance of non-
molecular T. vaginalis assays is more accurately predicated on disease prevalence than on 
symptomatic status. 
 
Detection of asymptomatic trichomoniasis is also important, because studies67,68 have documented 
persistent indolent T. vaginalis infection based on laboratory detection of the organism following 
previously negative test results in the face of sexual abstinence. Munson et al.49 stated that 27% of 
patients in a low-prevalence STI setting with antigen assay-negative/(retrospective) TMA-positive 
results returned for clinical STI evaluation. 
 
Two papers discuss this paradigm in the context of prevalent/incident T. vaginalis infection. A nine-
center study69 characterized the initial T. vaginalis prevalence as 14.6%. The cumulative 6-month 
incidence of T. vaginalis infection (defined as T. vaginalis detection in patients with either a negative T. 
vaginalis result at baseline or a positive result at baseline and receiving anti-trichomonad therapy) was 
7.5%. Patients more likely to have incident T. vaginalis infections included those with 
baseline HIV infection (relative risk, 1.59) and baseline T. vaginalis infection (relative risk, 3.37). 
Because nearly 50% of patients positive for T. vaginalis at baseline received therapy, the authors 
speculate that incident T. vaginalis was related to re-infection or treatment failure. Gaydos et al.70 
studied 304 female repeat participants in an internet STI screening program. Within this cohort, the T. 
vaginalis TMA detection rate was 7.9% during the first assessment, with 9.2% detection upon repeat 
testing (60% reporting symptoms). T. vaginalisdetection among repeat participants was also associated 
with previous detection of T. vaginalis (P < 0.05). 
 
Final notes on specimen collection 
Recent data from the CDC71 support the collection of vaginal swabs for laboratory detection of C. 
trachomatis and N. gonorrhoeae. Such collections are preferred for assessment of T. 
vaginalis infection; this preference is substantiated by data from Nye et al.45 Other studies in the 
literature espouse first-void urine as a viable specimen option for detection of T. vaginalis in females. 
Napierala et al.24 reported a 12.6% T. vaginalisdetection rate from first-void urine in contrast to 8.9% 
and 8.6% rates from endocervical and vaginal specimens, respectively. A follow-up assessment of 2,478 
females from a large metropolitan cohort (including both high- and low-prevalence locales)72 reported 
increased T. vaginalis detection from first-void urine (11.3%) compared to endocervical specimens 
(8.2%; P = 0.04) and a trend toward increased detection from first-void urine versus a combined 
endocervical/vaginal specimen data set (P = 0.06). The above-mentioned studies are limited because 
data analysis was based on the specimens collected by clinicians during routine medical practice; 
multiple specimens were not collected from the same patient. However, Andrea and Chapin50 reported 
11.5% and 3.2% T. vaginalis detection rates from female first-void urine and endocervical collection, 
respectively (P < 0.0002). 
 
When C. trachomatis and T. vaginalis detection rates were compared in a demographic (under age 21) 
in which T. vaginalis is not typically considered within an STI differential diagnosis (Fig. 2), the C. 
trachomatis detection rate among approximately 1,500 females was higher than that of T. 
vaginalis (P = 0.001). However, when the detection rates were stratified by specimen source,25 the T. 
vaginalis detection rate (11.2%) among nearly 300 females who were screened with first-void urine 
rivaled the rate for C. trachomatis (10.9%; P = 0.92). First-void urine screening seemingly eliminated a 
disparity between African American and Caucasian female demographics with respect to T. 
vaginalis detection. Overall, TMA detection of the parasite in African American majority geographic 
locales across a large metropolitan area was 11.7% compared to 9.0% in predominantly Caucasian 
locales (P = 0.004). When stratified by first-void urine collection, T. vaginalis detection rates exhibited 
minimal difference (14.4% and 12.5% in African American and Caucasian majority locales, 
respectively; P = 0.54).25 
 
Gaydos et al.73 described 3.7% detection of T. vaginalis RNA from 1,699 males using self-collected 
penile-meatal swabs in the context of an Internet screening program. Similar to previous studies of 
trichomoniasis epidemiology in males, the associated risk factors included age 30 to 39 years (odds 
ratio, 6.63) and age >40 years (odds ratio, 5.31). In a second cohort, Dize et al.74 investigated 
concomitant submission of self-collected penile-meatal swabs and first-void urine from 634 males. 
From 56 patients with detectable T. vaginalis infection via TMA, the swab sensitivity was 80.4% and the 
first-void urine sensitivity was 39.3%; similar disparities in sensitivity were observed for C. 
trachomatis and N. gonorrhoeae. 
Conclusion 
Evaluation of reports regarding past modalities for diagnosis of trichomoniasisis compromised by an 
evolving molecular reference standard. This is further confounded by analytical sensitivity differences 
between DNA and RNA amplification methods demonstrated both in vitro and in the clinical setting. 
However, these recently commercialized, highly accurate diagnostic modalities, particularly those 
based on TMA, are facilitating “new” outlooks on the “old” epidemiology of trichomoniasis. This clinical 
entity is now widely distributed in a geographic setting, in both genders, and in wide range of age 
demographics. Evidence increasingly supports the value of T. vaginalismolecular diagnostics in the 
assessment of both symptomatic and asymptomatic populations. In conclusion, molecular assays for 
trichomoniasis, including those adapted to laboratory-modified testing formats, have the potential to 
impact public health and clinical practice. 
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